Glenmark Pharmaceuticals Inc, the US-based unit of Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296), has launched its Acetylcysteine Injection, according to a Monday filing to the Indian stock exchanges.
Glenmark acquired the ANDA (abbreviated new drug application) for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) single-dose vials from Aspen Pharma USA.
The injection is expected to have the same therapeutic effect as Cumberland Pharmaceuticals' listed drug product Acetadote Injection.
As per the IQVIATM sales data, the Acetadote Injection achieved annual sales of around $15.2 million for the 12 months that ended in January.
Shares of the company were up nearly 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.